DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $72,000 | +71.4% | 832 | -41.0% | 0.00% | – |
| Q2 2022 | $42,000 | -6.7% | 1,411 | 0.0% | 0.00% | – |
| Q1 2022 | $45,000 | -97.6% | 1,411 | -96.7% | 0.00% | -100.0% |
| Q4 2021 | $1,880,000 | -11.1% | 42,161 | +0.6% | 0.00% | 0.0% |
| Q3 2021 | $2,114,000 | -35.7% | 41,910 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $3,288,000 | +34.1% | 41,910 | -2.4% | 0.00% | 0.0% |
| Q1 2021 | $2,451,000 | -16.0% | 42,932 | +23.2% | 0.00% | -25.0% |
| Q4 2020 | $2,918,000 | +2029.9% | 34,841 | +814.2% | 0.00% | – |
| Q3 2020 | $137,000 | +48.9% | 3,811 | 0.0% | 0.00% | – |
| Q2 2020 | $92,000 | – | 3,811 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |